1. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo
   Natalie R. Young et al, 2015, Targeted Oncology CrossRef
2. Beyond cytotoxic potency: disposition features required to design ADC payload
   Hao Sun et al, 2024, Xenobiotica CrossRef
3. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors
   Sandrine Hiret et al, 2018, Investigational New Drugs CrossRef
4. Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer
   Gustavo A. Arias-Pinilla et al, 2020, Scientific Reports CrossRef
5. Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer
   Said Abdullah Khelwatty et al, 2019, Oncotarget CrossRef
6. Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models
   Pei San Yee et al, 2019, Targeted Oncology CrossRef